MedTrace Logo

The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)

NCT01206257 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17513

Last updated 2013-06-11

No results posted yet for this study

Summary

This study is to collect the information of Ultravist® in the patients indicated for the coronary angiography or PCI, like rate of ADR in patients, the dose for different indications, image quality to prove Ultravist the good safety and effectivity

Conditions

  • Angiocardiography

Interventions

DRUG

Iopromide (Ultravist, BAY86-4877)

Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • China

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01206257 on ClinicalTrials.gov